-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314

Benzinga·10/21/2026 16:30:14
Listen to the news
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target from $322 to $314.